JOHN KIRKWOOD to Kidney Neoplasms
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Kidney Neoplasms.
Connection Strength
0.845
-
Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol. 2009 Jun 01; 27(16):2583-5.
Score: 0.235
-
Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Clin Exp Immunol. 1998 Dec; 114(3):347-54.
Score: 0.115
-
Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res. 1992 Feb 15; 52(4):851-6.
Score: 0.072
-
A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990 Oct; 8(10):1637-49.
Score: 0.065
-
Coumarin plus cimetidine: yet another angle for therapy of renal cell carcinoma. J Clin Oncol. 1987 Jun; 5(6):836-7.
Score: 0.052
-
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985 Feb; 45(2):863-71.
Score: 0.044
-
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005 Jan 01; 23(1):133-41.
Score: 0.044
-
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res. 2003 Mar; 9(3):947-54.
Score: 0.038
-
Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials. J Biol Response Mod. 1983; 2(6):528-39.
Score: 0.038
-
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med. 2002 Sep 02; 196(5):619-28.
Score: 0.037
-
Cancer immunotherapy: the interferon-alpha experience. Semin Oncol. 2002 Jun; 29(3 Suppl 7):18-26.
Score: 0.037
-
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001; 19(1):89-92.
Score: 0.033
-
A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1997 Jun; 20(3):251-3.
Score: 0.026
-
Interferons in the treatment of human cancer. J Clin Oncol. 1984 Apr; 2(4):336-52.
Score: 0.010